(19)
(11) EP 1 801 592 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.04.2009 Bulletin 2009/15

(45) Mention of the grant of the patent:
31.12.2008 Bulletin 2009/01

(21) Application number: 06110392.5

(22) Date of filing: 24.02.2006
(51) International Patent Classification (IPC): 
G01N 33/576(2006.01)
A61K 47/42(2006.01)
A61K 39/00(2006.01)
 C07K 16/10(2006.01)
A61K 47/48(2006.01)

(54)

Hepatitis C virus NS2/3 assay

Hepatitis C Virus NS2/3 Assay

Test du virus NS2/3 de l'hépatite C

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 21.12.2005 US 275284

(43) Date of publication of application:
27.06.2007 Bulletin 2007/26

(73) Proprietors:
  • Boehringer Ingelheim International GmbH
    55216 Ingelheim am Rhein (DE)
    Designated Contracting States:
    LI CY CZ DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR AT BE BG CH 
  • Boehringer Ingelheim Pharma GmbH & Co.KG
    55216 Ingelheim am Rhein (DE)
    Designated Contracting States:
    DE 

(72) Inventors:
  • Lamarre, Lyne
    Laval Québec H7S2G5 (CA)
  • Lagace, Lisette
    Laval Québec H7S2G5 (CA)
  • Thibeault, Diane
    Laval Québec H7S2G5 (CA)

(74) Representative: Hammann, Heinz et al
Boehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 173
55216 Ingelheim am Rhein
55216 Ingelheim am Rhein (DE)


(56) References cited: : 
US-A1- 2002 192 640
   
  • THIBEAULT D ET AL: "In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 49, 7 December 2001 (2001-12-07), pages 46678-46684, XP002221840 ISSN: 0021-9258
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).